Ganirelix
- Generic Name
- Ganirelix
- Brand Names
- Fyremadel, Orgalutran, Ganirelix Gedeon Richter
- Drug Type
- Small Molecule
- Chemical Formula
- C80H113ClN18O13
- CAS Number
- 124904-93-4
- Unique Ingredient Identifier
- IX503L9WN0
- Background
Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. Ganirelix is indicated for controlled ovarian hyperstimulation in assisted reproduction techniques. The first case of pregnancy achieved after the use of ganirelix in an assisted reprod...
- Indication
Ganirelix is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniques (ART).
- Associated Conditions
- -
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.
- Conditions
- Interventions
- First Posted Date
- 2024-10-11
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Ginefiv
- Target Recruit Count
- 144
- Registration Number
- NCT06637189
To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT06091436
- Locations
- 🇨🇳
The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital, Guangzhou, Guangdong, China
Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 20
- Registration Number
- NCT05751252
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
- Conditions
- Interventions
- Drug: Gonadorelin (also known as Lutrepulse)Drug: Ketoconazole Pill (also known as nizoral)Drug: GanirelixDrug: Corticorelin (also known as Acthrel)Drug: Dexamethasone injectionDrug: Hydrocortisone Injection (also known as solu-cortef)Drug: Dexamethasone PillDrug: Placebo oral tabletDrug: Cosyntropin Injectable ProductDrug: Saline SolutionDrug: Recombinant Human Luteinizing Hormone (also known as luveris)Drug: Saline solution for injection
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2023-11-07
- Target Recruit Count
- 5
- Registration Number
- NCT04037605
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States
Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient
- Conditions
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Reproductive & Genetic Hospital of CITIC-Xiangya
- Target Recruit Count
- 552
- Registration Number
- NCT03300518
- Locations
- 🇨🇳
Reproductive & Genetic Hospital of Citic-Xiangya, Changsha, Hunan, China
Hormonal Mechanisms of Sleep Restriction - Axis Study
- Conditions
- Interventions
- Drug: GonadorelinDrug: GanirelixDrug: Ketoconazole PillDrug: Dexamethasone InjectionDrug: CorticorelinDrug: Hydrocortisone InjectionDrug: DexamethasoneDrug: Placebo oral capsuleDrug: Cosyntropin Injectable ProductDrug: Saline SolutionDrug: Recombinant Human Luteinizing HormoneDrug: Saline Solution for Injection
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2024-04-23
- Target Recruit Count
- 80
- Registration Number
- NCT03142893
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States
Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol
- Conditions
- Interventions
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Chong Qing Reproducive and Genetic Institute
- Target Recruit Count
- 200
- Registration Number
- NCT02635607
Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation
- Conditions
- Interventions
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2018-03-23
- Lead Sponsor
- Michigan Reproductive Medicine
- Target Recruit Count
- 38
- Registration Number
- NCT02069808
- Locations
- 🇺🇸
Michigan Reproductive Medicine, Bloomfield Hills, Michigan, United States
Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial
- Conditions
- Interventions
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 150
- Registration Number
- NCT01816321
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Brussels, Belgium
🇻🇳University of Medicine and Pharmacy of Ho Chi Minh City, Ho Chi Minh City, Vietnam
Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Institut Universitari Dexeus
- Target Recruit Count
- 15
- Registration Number
- NCT01645241
- Locations
- 🇪🇸
Departamento de Obstetricia Ginecologia y Reproducción. Institut Universitari Dexeus, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.